Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.65 USD | +2.42% | +7.13% | -25.68% |
Financials (USD)
Sales 2024 * | 40.01M | Sales 2025 * | 97.75M | Capitalization | 164M |
---|---|---|---|---|---|
Net income 2024 * | -58M | Net income 2025 * | -26M | EV / Sales 2024 * | 4.09 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.67 x |
P/E ratio 2024 * |
-3.07
x | P/E ratio 2025 * |
-7.36
x | Employees | 136 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.93% |
Latest transcript on scPharmaceuticals Inc.
1 day | +1.57% | ||
1 week | +0.89% | ||
Current month | +1.57% | ||
1 month | -6.39% | ||
3 months | -10.81% | ||
6 months | -13.19% | ||
Current year | -27.59% |
Managers | Title | Age | Since |
---|---|---|---|
John Tucker
CEO | Chief Executive Officer | 61 | 16-12-31 |
Rachael Nokes
DFI | Director of Finance/CFO | 49 | 14-08-31 |
John Mohr
CTO | Chief Tech/Sci/R&D Officer | - | 17-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 13-12-31 | |
Klaus Veitinger
BRD | Director/Board Member | 62 | 17-11-20 |
John Tucker
CEO | Chief Executive Officer | 61 | 16-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +1.32% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 4.66 | +2.64% | 72 449 |
24-05-01 | 4.54 | +1.57% | 100,122 |
24-04-30 | 4.47 | -2.40% | 184,913 |
24-04-29 | 4.58 | +2.00% | 194,134 |
24-04-26 | 4.49 | +3.22% | 119,733 |
Delayed Quote Nasdaq, May 01, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.59% | 164M | |
+33.25% | 699B | |
+28.59% | 571B | |
-3.55% | 364B | |
+18.16% | 326B | |
+4.36% | 286B | |
+14.81% | 236B | |
+4.93% | 198B | |
-9.78% | 194B | |
-3.69% | 149B |
- Stock Market
- Equities
- SCPH Stock